• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    $5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying

    3/28/24 8:33:08 AM ET
    $LEGH
    $MG
    $MIRM
    $SNOW
    Homebuilding
    Consumer Discretionary
    Military/Government/Technical
    Consumer Discretionary
    Get the next $LEGH alert in real time by email

    Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    Snowflake

    • The Trade: Snowflake Inc. (NYSE:SNOW) CEO Sridhar Ramaswamy acquired a total of 31,542 shares an average price of $158.52. To acquire these shares, it cost around $5 million.
    • What’s Happening: On March 19, Redburn Atlantic analyst Alex Haissl downgraded Snowflake from Neutral to Sell and announced a $125 price target.
    • What Snowflake Does: Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers, including nearly 30% of the Fortune 500 as its customers.

    Legacy Housing

    • The Trade: Legacy Housing Corporation (NASDAQ:LEGH) Director Francisco Javier Coll acquired a total of 1,650 shares at an average price of $20.02. To acquire these shares, it cost around $33,033.
    • What’s Happening: On March 15, Legacy Housing reported worse-than-expected fourth-quarter financial results.
    • What Legacy Housing Does: Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities.

    Don’t forget to check out our premarket coverage here

    Mistras Group

    • The Trade: Mistras Group, Inc. (NYSE:MG) Interim President and CEO Manuel N. Stamatakis bought a total of 15,000 shares at an average price of $6.00. To acquire these shares, it cost around $90,000.
    • What’s Happening: On March 6, MISTRAS Group reported worse-than-expected fourth-quarter earnings.
    • What Mistras Group Does: MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure.

    Mirum Pharmaceuticals

    • The Trade: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt bought a total of 2,000 shares at an average price of $24.80. The insider spent around $49,600 to buy those shares.
    • What’s Happening: On March 13, The FDA approved the company’sLivmarli (maralixibat) oral solution for cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis (PFIC).
    • What Mirum Pharmaceuticals Does: Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases.

     

    Check This Out: How To Earn $500 A Month From Apple Stock

    Get the next $LEGH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LEGH
    $MG
    $MIRM
    $SNOW

    CompanyDatePrice TargetRatingAnalyst
    Snowflake Inc.
    $SNOW
    2/26/2026$275.00 → $282.00Buy
    Monness Crespi & Hardt
    Mirum Pharmaceuticals Inc.
    $MIRM
    2/18/2026$130.00Outperform
    RBC Capital Mkts
    Snowflake Inc.
    $SNOW
    1/12/2026$250.00Buy
    Goldman
    Snowflake Inc.
    $SNOW
    1/12/2026$250.00Overweight → Equal Weight
    Barclays
    Snowflake Inc.
    $SNOW
    1/8/2026Hold → Buy
    Argus
    Snowflake Inc.
    $SNOW
    12/4/2025$260.00 → $275.00Buy
    Monness Crespi & Hardt
    Legacy Housing Corporation
    $LEGH
    11/11/2025Market Outperform → Market Perform
    CJS Securities
    Snowflake Inc.
    $SNOW
    10/1/2025$275.00Overweight
    Wells Fargo
    More analyst ratings

    $LEGH
    $MG
    $MIRM
    $SNOW
    SEC Filings

    View All

    SEC Form 144 filed by Snowflake Inc.

    144 - Snowflake Inc. (0001640147) (Subject)

    3/10/26 9:38:16 AM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    SEC Form 144 filed by Snowflake Inc.

    144 - Snowflake Inc. (0001640147) (Subject)

    3/6/26 5:36:58 PM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    Mistras Group Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Mistras Group, Inc. (0001436126) (Filer)

    3/4/26 4:35:39 PM ET
    $MG
    Military/Government/Technical
    Consumer Discretionary

    $LEGH
    $MG
    $MIRM
    $SNOW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Snowflake Research Reveals 85% of Healthcare Leaders View Interoperability as Foundational to Scaling AI

    Findings underscore a turning point in AI adoption in healthcare, where achieving measurable efficiency and cost savings with AI depends on breaking down data silos across fragmented systems 85% of healthcare and public health agency leaders report that improving data sharing and interoperability is a higher priority today than it was two years ago as organizations scale AI and pursue broader operational and value-based care goals 77% of organizations have already invested or plan to invest in generative or agentic AI technologies, prioritizing high-impact use cases such as administrative workflow automation, clinical documentation, and revenue cycle operations More than half of re

    3/10/26 3:00:00 PM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    MISTRAS Group Issues Clarification Regarding Diluted EPS Excluding Special Items (Non-GAAP) Referenced During Q4 2025 Earnings Call

    PRINCETON JUNCTION, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE:MG), a global leader in technology-enabled industrial asset integrity and laboratory testing solutions, issues clarification regarding diluted EPS Excluding Special Items (Non-GAAP). During MISTRAS Group's Q4 2025 earnings conference call held on March 5, 2026, management inadvertently stated during the prepared remarks that the Company's Diluted EPS Excluding Special Items (non-GAAP) for the three months ended December 31, 2025 was $0.20 per share. The correct Diluted EPS Excluding Special Items (non-GAAP) for the period was $0.25 per share, as accurately reported in the Company's earnings press release

    3/5/26 12:38:10 PM ET
    $MG
    Military/Government/Technical
    Consumer Discretionary

    Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus

    - Phase 3 AZURE-1 enrollment complete - Phase 3 AZURE-4 screening complete - Topline AZURE-1 and AZURE-4 results expected in 2H 2026 - AZURE-1 and AZURE-4 to form the basis of Mirum's U.S. BLA Submission Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV). Achievement of these milestones confirms the expected timing of topline 24-week data in the second half of 2026. AZURE-1 and AZURE-4 together will form the basis of Mirum's U.S. BLA submission for br

    3/5/26 8:00:00 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGH
    $MG
    $MIRM
    $SNOW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Stamatakis Manuel N. covered exercise/tax liability with 814 shares, decreasing direct ownership by 0.16% to 509,795 units (SEC Form 4)

    4 - Mistras Group, Inc. (0001436126) (Issuer)

    3/10/26 3:26:00 PM ET
    $MG
    Military/Government/Technical
    Consumer Discretionary

    EVP & Chief Operating Officer Hammad Hanei Wail covered exercise/tax liability with 337 shares, decreasing direct ownership by 0.52% to 64,642 units (SEC Form 4)

    4 - Mistras Group, Inc. (0001436126) (Issuer)

    3/10/26 2:34:47 PM ET
    $MG
    Military/Government/Technical
    Consumer Discretionary

    SEC Form 4 filed by Chief Financial Officer Langbert Jon

    4 - Legacy Housing Corp (0001436208) (Issuer)

    3/10/26 2:18:13 PM ET
    $LEGH
    Homebuilding
    Consumer Discretionary

    $LEGH
    $MG
    $MIRM
    $SNOW
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 21, 2025 - FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease

    For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

    2/21/25 11:48:20 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGH
    $MG
    $MIRM
    $SNOW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heron Patrick J acquired 159,277 shares and bought $8,999,984 worth of shares (131,425 units at $68.48) (SEC Form 4)

    4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

    1/27/26 4:14:26 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Legal Officer Coggins Eileen Mary bought $143,250 worth of shares (15,000 units at $9.55) (SEC Form 4)

    4 - Mistras Group, Inc. (0001436126) (Issuer)

    9/25/25 3:53:59 PM ET
    $MG
    Military/Government/Technical
    Consumer Discretionary

    Executive Chairman Stamatakis Manuel N. bought $77,100 worth of shares (10,000 units at $7.71), increasing direct ownership by 3% to 384,299 units (SEC Form 4)

    4 - Mistras Group, Inc. (0001436126) (Issuer)

    6/6/25 3:59:38 PM ET
    $MG
    Military/Government/Technical
    Consumer Discretionary

    $LEGH
    $MG
    $MIRM
    $SNOW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Monness Crespi & Hardt reiterated coverage on Snowflake with a new price target

    Monness Crespi & Hardt reiterated coverage of Snowflake with a rating of Buy and set a new price target of $282.00 from $275.00 previously

    2/26/26 7:37:24 AM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    RBC Capital Mkts initiated coverage on Mirum Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of Mirum Pharmaceuticals with a rating of Outperform and set a new price target of $130.00

    2/18/26 7:54:16 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Snowflake with a new price target

    Goldman resumed coverage of Snowflake with a rating of Buy and set a new price target of $250.00

    1/12/26 8:18:29 AM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    $LEGH
    $MG
    $MIRM
    $SNOW
    Financials

    Live finance-specific insights

    View All

    MISTRAS Group Issues Clarification Regarding Diluted EPS Excluding Special Items (Non-GAAP) Referenced During Q4 2025 Earnings Call

    PRINCETON JUNCTION, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE:MG), a global leader in technology-enabled industrial asset integrity and laboratory testing solutions, issues clarification regarding diluted EPS Excluding Special Items (Non-GAAP). During MISTRAS Group's Q4 2025 earnings conference call held on March 5, 2026, management inadvertently stated during the prepared remarks that the Company's Diluted EPS Excluding Special Items (non-GAAP) for the three months ended December 31, 2025 was $0.20 per share. The correct Diluted EPS Excluding Special Items (non-GAAP) for the period was $0.25 per share, as accurately reported in the Company's earnings press release

    3/5/26 12:38:10 PM ET
    $MG
    Military/Government/Technical
    Consumer Discretionary

    MISTRAS Announces Fourth Quarter and Full Year 2025 Results

    Solid Quarterly Revenue Growth of 5.1%,with an Expansion in Gross Profit Margin of 190 Basis Points,Generating Net Income of $3.9 million and Earnings Per Diluted Share of $0.12, Achieving Record Fourth Quarter Adjusted EBITDA of $24.8 million PRINCETON JUNCTION, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE:MG), a global leader in technology-enabled industrial asset integrity and testing solutions, reported financial results for its fourth quarter and twelve months ended December 31, 2025. Fourth Quarter 2025 Key Figures* Revenue of $181.5 million, an increase of 5.1%, with growth across all segments Gross profit of $51.5 million, reflecting a gross margin of 28.4%

    3/4/26 4:29:27 PM ET
    $MG
    Military/Government/Technical
    Consumer Discretionary

    Snowflake Reports Financial Results for the Fourth Quarter and Full-Year of Fiscal 2026

    Revenue of $1.28 billion in the fourth quarter, representing 30% year-over-year growth Financial Highlights: Product revenue of $1.23 billion in the fourth quarter, representing 30% year-over-year growth Net revenue retention rate of 125% 733 customers with trailing 12-month product revenue greater than $1 million, representing 27% year-over-year growth 740 net new customer additions, representing 40% year-over-year growth Remaining performance obligations of $9.77 billion, representing 42% year-over-year growth Snowflake (NYSE:SNOW), the AI Data Cloud company, today announced financial results for its fourth quarter and full-year of fiscal 2026, ended January 31, 2026.

    2/25/26 4:05:00 PM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    $LEGH
    $MG
    $MIRM
    $SNOW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

    SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

    11/14/24 4:37:52 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

    SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

    11/14/24 12:55:40 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

    SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

    11/14/24 12:25:52 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEGH
    $MG
    $MIRM
    $SNOW
    Leadership Updates

    Live Leadership Updates

    View All

    Legacy Housing Announces Agreement to Purchase Assets of AmeriCasa Solutions, LLC and Addition of New Senior Management

    BEDFORD, Texas, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Legacy Housing Corporation (NASDAQ:LEGH), a leading manufacturer of community-focused manufactured homes, today announced entering into agreement to purchase the assets of AmeriCasa Solutions, LLC ("AmeriCasa Solutions") and its proprietary sales management platform, FutureHomeX®. Legacy Housing also announced the appointment of Norman Newton, AmeriCasa's Chief Executive Officer, as Legacy Housing's new Chief Revenue Officer. Legacy Housing is one of the largest producers of manufactured homes in the United States, distributing homes and "tiny houses" through a network of over 100 independent retailers and 12 company-owned stores, as well

    11/7/25 8:14:27 AM ET
    $LEGH
    Homebuilding
    Consumer Discretionary

    Snowflake Intelligence Brings Agentic AI to the Enterprise

    From Fortune 500 companies like Cisco, to global enterprises like Toyota Motor Europe, and sports teams like USA Bobsled/Skeleton Team, organizations in every industry are leveraging Snowflake Intelligence to democratize data and AI throughout their business Innovations such as Cortex Agents, Cortex Knowledge Extensions, and Snowflake managed MCP Server provide the building blocks that users need to create powerful, custom AI solutions More than 1,000 Snowflake customers have already leveraged Snowflake Intelligence to deploy over 12,000 AI agents across their businesses, and that number continues to grow Snowflake (NYSE:SNOW), the AI Data Cloud company, today announced that Snowflak

    11/4/25 9:10:00 AM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology

    USA Bobsled/Skeleton Taps Snowflake Intelligence to Redefine Speed and Precision on Ice

    Winter is coming! USABS will leverage Snowflake's world-class data and AI platform to gain crucial insights to support athletes, optimize sled technology and enhance strategic decision-making on ice USA Bobsled/Skeleton (USABS) selects Snowflake as the Official Data Cloud Provider aligning shared values of speed and excellence in the run up to the Olympic and Paralympic Winter Games Milano Cortina 2026 Snowflake's technology will provide coaches with fast, actionable data to make micro-adjustments to athlete technique Partnership extends on Snowflake's commitment to bringing best-in-class innovation to Team USA and the LA28 Olympic and Paralympic Games as their Official Data Collab

    11/3/25 9:05:00 AM ET
    $SNOW
    Computer Software: Prepackaged Software
    Technology